"Anthos' Safer Blood Thinner Reduces Bleeding Risk in Race for Anticoagulant Development"
TL;DR
Anthos Therapeutics' investigational anticoagulant has shown promising results in a mid-stage safety study, significantly reducing the risk of bleeding compared to Xarelto. This new class of anticoagulants aims to provide patients with a safer option for preventing stroke and blood clots, addressing one of the major concerns associated with current blood thinners.
Topics:healthhealthcare#anthos-therapeutics#anticoagulants#bleeding-risk#healthcare#stroke-prevention#xarelto
- Anthos' blood thinner cuts the risk of bleeding amid race to develop safer anticoagulants Endpoints News
- Apixaban Cuts Stroke but Ups Bleeding in Subclinical AF Medscape
- Anthos stroke drug appears safer than common blood thinner in mid-stage trial STAT
- ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF TCTMD
- DOAC Cuts Stroke Risk From Subclinical Afib Medpage Today
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News